Archive

Improving medication use – ESCP Day 3 Highlights

Written by | 29 Oct 2024

Therapeutic advances in lung cancer  Molecular testing before the start of treatment is good clinical practice (GCP) and confers considerable benefits in survival, according to Professor Joanna Chorostowska-Wynimko […]

A simple test can predict whether smokers will manage to quit

Written by | 19 Aug 2024

Data from nearly 6000 smokers with cancer show that it may be easier to predict who will stop smoking than was previously thought. It is often important to […]

Lung cancer – urgent action required to get back on track

Written by | 3 Feb 2022

Two recent reports show how hard lung cancer outcomes have been impacted as a result of the covid-19 pandemic, according to Professor Robert Rintoul, chair of the UK […]

Air pollution linked to rise of lung cancer

Written by | 6 Dec 2021

Findings also reveal decline in smoking led to decrease in another type of lung cancer. An international team of scientists, led by Nanyang Technological University, Singapore (NTU Singapore), […]

“Never smoker” lung cancer could respond to drugs already available

Written by | 6 Oct 2021

Drugs which are already (U.S.) Food and Drug Administration (FDA) approved could be effective in treating of lung cancer in “never-smokers,” researchers reported on Sept. 30, 2021 in […]

The impact of covid-19 on lung cancer care

Written by | 4 Feb 2021

Delayed diagnoses and more patients with advanced cancers were consequences of the coronavirus pandemic, according to Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado. The coronavirus […]

The changing treatment landscape in lung cancer

Written by | 3 Feb 2021

Modern lung cancer treatment has changed the outlook for lung cancer patients considerably and interesting trial results are expected this year, according to Dr Erin Schenk, Assistant Professor, […]

Improved disease-free survival with osimertinib in EGFR+ lung cancer

Written by | 2 Feb 2021

Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado describes the results of the ADAURA trial and the implications for her practice. The other trial that has […]

Immunotherapy vs chemotherapy for lung cancer: 5-year survival

Written by | 1 Feb 2021

IMI interviewed Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado to find out about key trial results in lung cancer and the implications for patient care. […]

Targeted capmatinib shows efficacy for treating lung cancer with certain mutations

Written by | 19 Nov 2020

Researchers report that capmatinib, a targeted therapy, appears to provide clinical benefit to patients who have advanced lung cancer with specific gene mutations. Their findings appear in the […]

Lung cancer or covid-19? Messages for primary care

Written by | 18 Sep 2020

The key message for primary care is about using the guidance document, Differentiation of the Cs to enable health care professionals to triage patients more accurately, says Professor David Baldwin, […]

Early diagnosis of lung cancer in the time of covid-19

Written by | 16 Sep 2020

The lung cancer service has been very seriously affected by the coronavirus pandemic, in particular, lung cancer referrals have fallen sharply during lockdown, says Professor David Baldwin, chairman […]

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.